These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 18973064)
1. Epidemiology of Guillain-Barré syndrome in the province of Quebec. Deceuninck G; Boucher RM; De Wals P; Ouakki M Can J Neurol Sci; 2008 Sep; 35(4):472-5. PubMed ID: 18973064 [TBL] [Abstract][Full Text] [Related]
2. Risk of Guillain-Barré syndrome following serogroup C meningococcal conjugate vaccine in Quebec, Canada. De Wals P; Deceuninck G; Boucher RM; Ouakki M Clin Infect Dis; 2008 Apr; 46(8):e75-7. PubMed ID: 18444843 [TBL] [Abstract][Full Text] [Related]
3. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. De Wals P; Deceuninck G; Toth E; Boulianne N; Brunet D; Boucher RM; Landry M; De Serres G JAMA; 2012 Jul; 308(2):175-81. PubMed ID: 22782419 [TBL] [Abstract][Full Text] [Related]
5. Relationship between occurrence of Guillain-Barre syndrome and mass campaign of measles and rubella immunization in Iranian 5-14 years old children. Esteghamati A; Gouya MM; Keshtkar AA; Mahoney F Vaccine; 2008 Sep; 26(39):5058-61. PubMed ID: 18662736 [TBL] [Abstract][Full Text] [Related]
6. Incidence of Guillain-Barré syndrome in Ontario and Quebec, 1983-1989, using hospital service databases. McLean M; Duclos P; Jacob P; Humphreys P Epidemiology; 1994 Jul; 5(4):443-8. PubMed ID: 7918815 [TBL] [Abstract][Full Text] [Related]
8. Population incidence of Guillain-Barré syndrome in parts of China: three large populations in Jiangsu province, 2008-2010. Chen Y; Ma F; Zhang J; Chu X; Xu Y Eur J Neurol; 2014; 21(1):124-9. PubMed ID: 24102733 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. De Wals P; De Serres G; Niyonsenga T JAMA; 2001 Jan; 285(2):177-81. PubMed ID: 11176810 [TBL] [Abstract][Full Text] [Related]
10. Guillain-Barré syndrome: background incidence rates in The Netherlands. van der Maas NA; Kramer MA; Jacobs BC; van Soest EM; Dieleman JP; Kemmeren JM; de Melker HE; Sturkenboom MC J Peripher Nerv Syst; 2011 Sep; 16(3):243-9. PubMed ID: 22003939 [TBL] [Abstract][Full Text] [Related]
11. Incidence study of Guillain-Barré syndrome in the province of Ferrara, Northern Italy, between 2003 and 2017. A 40-year follow-up. Granieri E; Andreasi NG; De Martin P; Govoni V; Castellazzi M; Cesnik E; Pugliatti M; Casetta I Neurol Sci; 2019 Mar; 40(3):603-609. PubMed ID: 30617450 [TBL] [Abstract][Full Text] [Related]
12. Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada. De Wals P; Deceuninck G; Lefebvre B; Tsang R; Law D; De Serres G; Gilca V; Gilca R; Boulianne N Clin Infect Dis; 2017 May; 64(9):1263-1267. PubMed ID: 28207068 [TBL] [Abstract][Full Text] [Related]
13. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(41):1120-4. PubMed ID: 17060898 [TBL] [Abstract][Full Text] [Related]
14. The frequency of clinical variants of Guillain-Barré syndrome in Ferrara, Italy. Govoni V; Granieri E; Tola MR; Casetta I; Ruppi P; Vaghi L J Neurol; 1999 Nov; 246(11):1010-4. PubMed ID: 10631631 [TBL] [Abstract][Full Text] [Related]
15. Guillain-Barré syndrome following the 2009 pandemic monovalent and seasonal trivalent influenza vaccination campaigns in Spain from 2009 to 2011: outcomes from active surveillance by a neurologist network, and records from a country-wide hospital discharge database. Alcalde-Cabero E; Almazán-Isla J; García López FJ; Ara-Callizo JR; Avellanal F; Casasnovas C; Cemillán C; Cuadrado JI; Duarte J; Fernández-Pérez MD; Fernández Ó; Merino JA; Montero RG; Montero D; Pardo J; Rodríguez-Rivera FJ; Ruiz-Tovar M; de Pedro-Cuesta J; BMC Neurol; 2016 May; 16():75. PubMed ID: 27206524 [TBL] [Abstract][Full Text] [Related]
16. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Hughes RA; Charlton J; Latinovic R; Gulliford MC Arch Intern Med; 2006 Jun; 166(12):1301-4. PubMed ID: 16801513 [TBL] [Abstract][Full Text] [Related]
17. The incidence and triggers of adult-onset Guillain-Barré syndrome in southwestern Finland 2004-2013. Sipilä JO; Soilu-Hänninen M Eur J Neurol; 2015 Feb; 22(2):292-8. PubMed ID: 25196425 [TBL] [Abstract][Full Text] [Related]
18. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2006 Apr; 55(13):364-6. PubMed ID: 16601664 [TBL] [Abstract][Full Text] [Related]
19. Guillain-Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. Al-Hakem H; Sindrup SH; Andersen H; de la Cour CD; Lassen LL; van den Berg B; Jacobs BC; Harbo T J Neurol; 2019 Feb; 266(2):440-449. PubMed ID: 30536111 [TBL] [Abstract][Full Text] [Related]
20. Guillain-BarrÉ Syndrome After Immunization in Canadian Children (1996-2012). Top KA; Desai S; Moore D; Law BJ; Vaudry W; Halperin SA; Bettinger JA; Pediatr Infect Dis J; 2015 Dec; 34(12):1411-3. PubMed ID: 26379167 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]